Story perspectives

Pfizer Strikes $6 Billion Cancer Drug Deal in China

5/20/2025

49 3

Summary

Story summary

Pfizer Inc. has entered a $6 billion licensing agreement with China's 3SBio for the cancer drug SSGJ-707.
The deal includes an upfront payment of $1.25 billion and potential performance-based payments of $4.8 billion.
While 3SBio retains rights in China, Pfizer may explore sales opportunities there in the future.
Pfizer will invest $100 million in 3SBio and manufacture the drug in North Carolina and Kansas.
The company has invested over $1.5 billion in China, enhancing its footprint in the pharmaceutical sector.

1 of 1

Story summary

Pfizer Inc. has entered a $6 billion licensing agreement with China's 3SBio for the cancer drug SSGJ-707.
The deal includes an upfront payment of $1.25 billion and potential performance-based payments of $4.8 billion.
While 3SBio retains rights in China, Pfizer may explore sales opportunities there in the future.
Pfizer will invest $100 million in 3SBio and manufacture the drug in North Carolina and Kansas.
The company has invested over $1.5 billion in China, enhancing its footprint in the pharmaceutical sector.